Metabolic complications continue to play a major role in the management of HIV infection.
Dyslipidemia associated with HIV infection and with the use of combined antiretroviral …

Ezetimibe is the first agent used in hypercholesterolemia treatment known to lower intestinal
cholesterol uptake that is able to inhibit NPC1L1 transport proteins in the brush boarder of …

Hypercholesterolemia frequently occurs in patients treated with efavirenz who cannot be
treated adequately with statins because of drug interactions. These patients may benefit …

Background HIV-infected patients on antiretroviral therapy frequently develop dyslipidemias
and, despite therapy with potent lipid-lowering agents, a high percentage does not achieve …

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. Asthis
population lives longer, coronary heart disease has become an important comorbid …

Dyslipidemia now is recognized as a significant potential adverse event in HIV-infected
patients who are receiving antiretroviral therapy. HIV-infected persons who have …

Background: Ezetimibe inhibits intestinal absorption of cholesterol. Methods: Multicentered
double-blind, randomized, placebo-controlled, crossover study to determine the short-term …

Objectives: HIV infection and exposure to certain antiretroviral drugs is associated with
dyslipidemia and increased risk for coronary events. Whether this risk is mediated by highly …

Many infections favor or are directly implicated with lipid metabolism perturbations and/or
increased risk of coronary heart disease (CHD). HIV itself has been shown to increase …

Ezetimibe (EZE), a selective inhibitor of intestinal cholesterol absorption, is mostly used in
combination with statins across various patient populations. Besides its low-density …